Current approaches for the treatment with thyroid hormone analogs

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 2, Issue 1, 2008, Pages 1-8

  Plikat, Katharina ^a   Wrede, Christian E ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Analogs; Metabolic syndrome; NTIS; Thyroid hormone; TRH

Indexed keywords

2 INDOLECARBOXYLIC ACID; ALBUMIN; AMIODARONE; GC 3707; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HORMONE RECEPTOR STIMULATING AGENT; INTEGRIN; LIOTHYRONINE; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONTIRELIN; OXAMIC ACID; PHENYLPYRUVIC ACID; PLACEBO; PREALBUMIN; PROTIRELIN; PROTIRELIN DERIVATIVE; PROTIRELIN RECEPTOR; TALTIRELIN; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROID HORMONE RECEPTOR STIMULATING AGENT; THYROXINE; THYROXINE BINDING GLOBULIN; TIRATRICOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATAXIA; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN DAMAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CRITICALLY ILL PATIENT; DEPRESSION; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; EXPERIMENTAL MODEL; GLUCOSE HOMEOSTASIS; HEART ATRIUM FIBRILLATION; HORMONE BINDING; HUMAN; HYPERTHYROIDISM; LIPID ANALYSIS; MEDICAL DECISION MAKING; MEMBRANE STABILIZATION; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATENT; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SPINE DISEASE; SPINOCEREBELLAR DEGENERATION; THYROID HORMONE SYNTHESIS; WAKEFULNESS;

EID: 42149111713     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221408783421282     Document Type: Review

References (104)

1. St Germain DL, Galton VA. The deiodinase family of selenoproteins. Thyroid 1997; 7: 655-668.
2. Larsen PR, Berry MJ. Nutritional and hormonal regulation of thyroid hormone deiodinases. Annu Rev Nutr 1995; 5: 323-352.
3. Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 1993; 14: 184-193.
4. Cheng SY. Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends Endocrinol Metab 2005; 16: 176-182.
5. Mitsuhashi T, Tennyson GE, Nikodem VM. Alternative splicing generates messages encoding rat c-erbA proteins that do not bind thyroid hormone. Proc Natl Acad Sci USA 1988; 85: 5804-5808.
6. Wondisford FE. Thyroid hormone action: insight from transgenic mouse models. J Investig Med 2003; 51: 215-220.
7. Zhang XY, Kaneshige M, Kamiya Y, Kaneshige K, McPhie P, Cheng SY. Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant Beta receptor. Mol Endocrinol 2002; 16: 2077-2092.
8. Bradley DJ, Towle HC, Young WS, Alpha and beta thyroid hormone receptor (TR) gene expression during auditory neurogenesis: evidence for TR isoform-specific transcriptional regulation in vivo. Proc Natl Acad Sci USA 1994; 91: 439-443.
9. Bradley DJ, Towle HC, Young WS. Spatial and temporal expression of alpha- and beta-thyroid hormone receptor mRNAs, including the beta 2-subtype, in the developing mammalian nervous system. J Neurosci 1992; 12: 2288-2302.
10. Williams GR. Cloning and characterization of two novel thyroid hormone receptor beta isoforms. Mol Cell Biol 2000; 20: 8329-8342.
11. Koenig RJ, Lazar MA, Hodin RA, et al. Inhibition of thyroid hormone action by a non-hormone binding c-erbA protein generated by alternative mRNA splicing. Nature 1989; 337: 659-661.
12. Hodin RA, Lazar MA, Chin WW. Differential and tissue-specific regulation of the multiple rat c-erbA messenger RNA species by thyroid hormone. J Clin Invest 1990; 85: 101-105.
13. Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am 1998; 27: 51-62.
14. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327: 94-98.
15. Wikstrom L, Johansson C, Salto C, et al. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. Embo J 1998; 17: 455-461.
16. Johansson C, Gothe S, Forrest D, Vennstrom B, Thoren P. Cardiovascular phenotype and temperature control in mice lacking thyroid hormone receptor-beta or both alpha1 and beta. Am J Physiol. 1999; 276: H2006-2012.
17. Forrest D, Hanebuth E, Smeyne RJ, et al. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function. Embo J 1996; 15: 3006-3015.
18. Brent GA. Tissue-specific actions of thyroid hormone: insights from animal models. Rev Endocr Metab Disord 2000; 1: 27-33.
19. Gothe S, Wang Z, Ng L, et al. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev 1999; 13: 1329-1341.
20. Gauthier K, Chassande O, Plateroti M, et al. Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development. Embo J 1999; 18: 623-631.
21. Abrams JJ, Grundy SM. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 1981; 22: 323-338.
22. Ness GC, Lopez D, Chambers CM, et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochem Pharmacol 1998; 56: 121-129.
23. Lerman J, Pitt-Rivers R. Physiologic activity of triiodo-and tetraiodo-thyroacetic acid in human myxedema. J Clin Endocrinol Metab 1956; 16: 1470-1479.
24. Underwood AH, Emmett JC, Ellis D, et al. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 1986; 324: 425-429.
25. Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlan TS. A high-affinity subtype selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998; 5: 299-306.
26. Baxter JD, Webb P, Grover G, Scanlan TS. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 2004; 15: 154-157.
27. Trost SU, Swanson E, Gloss B, et al. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000; 141: 3057-3064.
28. Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005; 102: 10297-10302.
29. Columbano A, Pibiri M, Deidda M, et al. The thyroid hormone receptor-beta agonist GC-1 induces cell proliferation in rat liver and pancreas. Endocrinology 2006; 147: 3211-3218.
30. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 2005; 46: 356-360.
31. Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine. Endocrinology 2004; 145: 1656-1661.
32. Grover GJ, Mellstrom K, Malm J. Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc Drug Rev 2005; 23: 133-148.
33. Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 2003; 00: 10067-10072.
34. Li YL, Litten C, Koehler KF, et al. Thyroid receptor ligands. Part 4: 4′-amido bioisosteric ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem Lett 2006; 16: 884-886.
35. Garg N, Li YL, Garcia Collazo AM, et al. Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141. Bioorg Med Chem Lett 2007; 17: 4131-4134.
36. Haynes, N.E., Kertesz, D.J, Pietranico-Cole, S.L., Quian, Y., Scott, N.R., So,S.S., Thakkar, K. C. Tilley J. W.: WO07009913 (2007).
37. Aspnes, G.E., Chiang, Y.-C.P.: FP129733 (2003).
38. Hangeland, J., Zhang, M., Caringal, Y., Ryono, D., Li, Y.-L., Malm, J., Liu,Y., Garg, N., Litten, C., Collazo, G.M.A., Koehle, R. K.: US20066989402 (2006).
39. Chiang, Y.-C.P., Dow, R.L.:.WO030051971 (2003).
40. Chiang, Y.-C.P., Aspnes, G.E., Estep, K.G.: US20077202275B2 (2007).
41. Stephan ZF, Yurachek EC, Sharif R, Wasvary JM, Steele RE, Howes C. Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. Biochem Pharmacol 1992; 43: 1969-1974.
42. Erion MD, Cable EE, Ito BR, et al. From the cover: Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007; 104: 15490-15495.
43. Webb P, Nguyen NH, Chiellini G, et al. Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol 2002; 83: 59-71
44. Estebanez-Perpina E, Arnold LA, Jouravel N, et al. Structural insight into the mode of action of a direct inhibitor of co regulator binding to the thyroid hormone receptor. Mol Endocrinol 2007; 6: 1782-3305.
45. Koehler K, Gordon S, Brandt P, et al. Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. J Med Chem 2006; 49: 6635-6637.
46. Malm J, Gordon S, Brandt P, et al. Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg Med Chem Lett 2007; 17: 2018-2021.
47. Malm, J., Litten, C., Apelqvist, T., Hedfors, A., Brandt, P., Edvinsson, K., Brandt P., Edvinsson, K., Gordon, S.: US20067005538 (2006).
48. Davis PJ, Shih A, Lin HY, Martino LJ, Davis FB. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 2000; 275: 38032-38039.
49. Lin HY, Davis FB, Gordinier JK, Martino LJ, Davis PJ. Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells. Am J Physiol 1999; 276: C1014-1024.
50. Bergh JJ, Lin HY, Lansing L, et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005; 146: 2864-2871
51. Cody V, Davis PJ, Davis FB. Molecular modeling of the thyroid hormone interactions with alpha v beta 3 integrin. Steroids 2007; 72: 165-170
52. Davis FB, Tang HY, Shih A, et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006; 66: 7270-7275
53. Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X. Proangiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 2006; 25: 407-413
54. Fone KC, Johnson JV, Marsden CA, Bennett GW. Comparative behavioural and biochemical effects of repeated intrathecal administration of thyrotrophin-releasing hormone (TRH) or two analogues of TRH in adult rats. Neuropharmacology 1989; 28: 867-875.
55. Dyess EM, Segerson TP, Liposits Z, et al. Triiodothyronine exerts direct cell-specific regulation of thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus. Endocrinology 1988; 23: 2291-2297.
56. Feng P, Li QL, Satoh T, Wilber JF. Ligand (T3) dependent and independent effects of thyroid hormone receptors upon human TRH gene transcription in neuroblastoma cells. Biochem Biophys Res Commun 1994; 200: 171-177.
57. Hollenberg AN, Monden T, Flynn TR, Boers ME, Cohen O, Wondisford FE. The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. Mol Endocrinol 1995; 9: 540-550.
58. Gershengorn MC. Mechanism of signal transduction by TRH. Ann N Y Acad Sci 1989; 553: 191-196.
59. Wilber JF, Pei F, Qiao-Ling L, Zhan XS. The thyrotropin-releasing hormone gene - differential regulation, expression, and function in hypothalamus and two unexpected extrahypothalamic loci, the heart and testis. Trends Endocrinol Metab 1996; 7: 93-100.
60. Cao J, O'Donnell D, Vu H, et al. Cloning and characterization of a cDNA encoding a novel subtype of rat thyrotropin-releasing hormone receptor. J Biol Chem 1998; 273: 32281-32287.
61. Harder S, Lu X, Wang W, Buck F, Gershengorn MC, Bruhn TO.) Regulator of G protein signaling 4 suppresses basal and thyrotropin releasing-hormone (TRH)-stimulated signaling by two mouse TRH receptors, TRH-R(1) and TRH-R(2). Endocrinology 2001; 142: 1188-1194.
62. Bidaud I, Lory P, Nicolas P, Bulant M, Ladram A. Characterization and functional expression of cDNAs encoding thyrotropin-releasing hormone receptor from Xenopus laevis. Eur J Biochem 2002; 269: 4566-4576.
63. Engel S, Gershengorn MC. Thyrotropin-releasing hormone and its receptors - a hypothesis for binding and receptor activation. Pharmacol Ther 2007; 113: 410-419.
64. Sun Y, Lu X, Gershengorn MC. Thyrotropin-releasing hormone receptors similarities and differences. J Mol Endocrinol 2003; 30: 87-97.
65. Gary KA, Sevarino KA, Yarbrough GG, Prange AJ Jr, Winokur A. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther 2003; 305: 410-416.
66. Nillni EA, Sevarino KA. The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev 1999; 20: 599-648.
67. Breese GR, Cott JM, Cooper BR, Prange AJ Jr, Lipton MA, Plotnikoff NP. Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs. J Pharmacol Exp Ther 1975; 193: 11-22.
68. Horita A. An update on the CNS actions of TRH and its analogs. Life Sci 1998; 62: 1443-1448.
69. Heuer H, Schafer MK, O'Donnell D, Walker P, Bauer K. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol 2000; 428: 319-336.
70. Zeng H, Schimpf BA, Rohde AD, Pavlova MN, Gragerov A, Bergmann JE. Thyrotropin-releasing hormone receptor 1 deficient mice display increased depression and anxiety like behavior. Mol Endocrinol 2007; 21 (11): 2795-2804.
71. Kastin AJ, Ehrensing RH, Schalch DS, Anderson MS. Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone. Lancet 1972; 2: 740-742.
72. Prange AJ, Lara PP, Wilson IC, Alltop LB, Breese GR. Effects of thyrotropin-releasing hormone in depression. Lancet 1972; 2: 999-1002.
73. Callahan AM, Frye MA, Marangell LB, et al. Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. Biol Psychiatry 1997; 41: 264-272.
74. Lloyd RL, Pekary AE, Sattin A, Amundson T. Antidepressant effects of thyrotropin-releasing hormone analogues using a rodent model of depression. Pharmacol Biochem Behav 2001; 70: 15-22.
75. Naftchi NE. Prevention of damage in acute spinal cord injury by peptides and pharmacologic agents. Peptides 1982; 3: 235-247.
76. Faden AI, Vink R, McIntosh TK. Thyrotropin-releasing hormone and central nervous system trauma. Ann N Y Acad Sci 1989; 553: 380-384.
77. Pitts LH, Ross A, Chase GA, Faden AI. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 1995; 12: 235-243
78. Sobue I, Takayanagi T, Nakanishi T, et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci 1983; 61: 235-248.
79. Hashida T, Yamada M, Hashimoto K, et al. A novel TRH-PFTAIRE protein kinase 1 pathway in the cerebellum: subtractive hybridization analysis of TRH-deficient mice. Endocrinology 2002; 143: 2808-2811.
80. Shibusawa, N, Hashimoto K, Yamada M. Thyrotropin-releasing hormone (TRH) in the cerebellum. Cerebellum: 2007; 23: 1-12.
81. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, van den BG. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003; 88: 3202-3211.
82. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, van den BG. Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 2005; 90: 4559-4565
83. Van den Berghe G, Wouters P, Weekers F, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84: 1311-1323.
84. Plikat K, Langgartner J, Buettner R, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism 2007; 56: 239-244.
85. Bundgaard, H., Moss, J.: US5405834 (1995).
86. Heya, T., Okada, H., Ogawa, Y.: US5652220 (1997).
87. Spatola, A., Lankiewicz, L., Labroo, V.M., Vonhof, S.: US5244884 ( 1993)
88. Prokai, L.: US20067067257 (2006).
89. Suzuki M, Sugano H, Matsumoto K, Yamamura M, Ishida R. Synthesis and central nervous system actions of thyrotropin-releasing hormone analogues containing a dihydroorotic acid moiety. J Med Chem 1990; 33: 2130-2137.
90. Tanabe M, Tokuda Y, Takasu K, Ono K, Honda M, Ono H. The synthetic TRH analogue taltirelin exerts modality-specific antinociceptive effects via distinct descending monoaminergic systems. Br J Pharmacol 2007; 150: 403-414.
91. Kinoshita K, Watanabe Y, Yamamura M, Matsuoka Y. TRH receptor agonists ameliorate 3-acetylpyridine-induced ataxia through NMDA receptors in rats. Eur J Pharmacol 1998; 343: 129-133.
92. Nakamura T, Honda M, Kimura S, Tanabe M, Oda S, Ono H. Taltirelin improves motor ataxia independently of monoamine levels in rolling mouse nagoya, a model of spinocerebellar atrophy. Biol Pharm Bull 2005; 28: 2244-2247.
93. Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997; 17: 6401-6408.
94. Urayama A, Yamada S, Kimura R, Zhang J, Watanabe Y. Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL/6J mice. Life Sci 2002; 72: 601-607.
95. Hennies HH, Flohe L. Effects of the thyroliberin analogue CG 3703 on noradrenergic and serotoninergic transmission in rodents. Biochem Pharmacol 1982; 31: 2430-2432.
96. McIntosh TK, Vink R, Faden AI. Beneficial effect of the TRH analog CG-3703 on outcome and survival following traumatic brain injury in rats. Prog Clin Biol Res 1988; 264: 415-420.
97. Ogasawara T, Ukai Y, Tamura M, Kimura K. NS-3 (CG3703), an analog of thyrotropin-releasing hormone, ameliorates cognitive impairment in rats. Pharmacol Biochem Behav 1995; 50: 499-503.
98. Richl J, Honda K, Kwan M, Hong J, Mignot E, Nishino S. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000; 23: 34-45.
99. Kaur N, Lu X, Gershengorn MC, Jain R. Thyrotropin-releasing hormone (TRH) analogues that exhibit selectivity to TRH receptor subtype 2. J Med Chem 2005; 48: 6162-6165.
100. Hinkle PM, Pekary AE, Senanayaki S, Sattin A. Role of TRH receptors as possible mediators of analeptic actions of TRH-like peptides. Brain Res 2002; 935: 59-64.
101. Schmitmeier S, Thole H, Hader A, Bauer K. Purification and characterization of the thyrotropin-releasing hormone (TRH)-degrading serum enzyme and its identification as a product of liver origin. Eur J Biochem. 2002; 269: 1278-1286.
102. Kelly JA, Slator GR, Tipton KF, Williams CH, Bauer K. Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides. J Biol Chem 2000; 275: 16746-16751.
103. Kelly J: US2006293247 (2006).
104. Scalabrino GA, Hogan N, O'Boyle KM, et al. Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone. Neuropharmacology 2007; 52: 1472-1481.